DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Gilead Sciences (NASDAQ: GILD)



company name or ticker
Company Photos
(Click to zoom)

Johnson & Johnson's Earnings: The Good, The Bad and The Ugly

Johnson & Johnson reported a mixed first-quarter this week. Here is what investors need to know going forward.

The Best Stock to Invest in Hep C

In the multibillion-dollar market for hepatitis C, this company stands above the crowd.

3 Biotech Stocks Under $10 with Amazing Growth Prospects - Analyst Blog

Gilead Sciences Reminds Me Of Apple Circa June 2013

Analyst Wants Proof On Arrowhead Research's Hepatitis B Drug

J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Pres

J.P. Morgan, Bank of America, Gilead Sciences and Actavis are part of Zacks Earnings Preview: - Press Releases

Project $3 Million - Portfolio Management, New Purchase

XLV, MRK, GILD, UNH: ETF Outflow Alert

Lumber Prices Fall Sharply: Implications For Bonds And Different Stock Market Sectors

Gilead Sciences Sparks Analyst Dispute Over Hep C Forecasts

See More Articles...